$5.1 million given to UBC to pursue coronavirus research

The federal government has provided researchers at the University of British Columbia with a total of $5.1 million in funding towards research on detecting, managing, and reducing the transmission of the COVID-19 coronavirus.

UBC researchers were initially provided with $2.8 million on March 6, but that has since been topped off with an additional $2.3 million, as of this week. The funding will be split amongst research teams led by Dr. Richard Lester, Dr. Srinivas Murthy, Natalie Prystajecky and Dr. Mel Krajden, Yue Qian, Horacio Bach, Artem Cherkasov, Eric Jan, Jeffrey Joy, and Dr. James Russell.

“We are very grateful for this additional investment through the federal government’s emergency research funding,” said Gail Murphy, UBC vice-president of research and innovation, in a statement.

“This provides researchers at UBC and across the country with resources to gain critical insights into COVID-19 and help to develop treatments and prevent its spread.”

This includes $999,000 using artificial intelligence to perform “deep docking” research that identifies the compounds that could potentially inhibit the main enzyme that allows SARS-CoV-2 virus – the scientific name of the COVID-19 virus – to survive.

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)